We are live on ! Find out more

Ardelyx

ARDX

Market cap $829M

3.21 USD

+0.12

3.88%

At close Updated Oct 20, 4:00 PM EDT

Pre-market

After hours

3.24

+0.03

0.93%

1 day

3.88%

5 days

3.55%

1 month

-8.29%

3 months

-36.94%

6 months

-49.05%

Year to date

-47.8%

1 year

-37.06%

5 years

191.82%

10 years

-76.4%

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 489

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0.7%

Neutral 93.8%

Negative 5.6%

Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX

NEW YORK, Oct. 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

New York, New York--(Newsfile Corp. - October 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ardelyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX

ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026

A securities class action chronicles how Ardelyx allegedly reaffirmed billion-dollar sales targets for IBSRELA and XPHOZAH across 19 months while payer prior authorization and step edit barriers were allegedly slowing new-patient starts A securities class action chronicles how Ardelyx allegedly reaffirmed billion-dollar sales targets for IBSRELA and XPHOZAH across 19 months while payer prior authorization and step edit barriers were allegedly slowing new-patient starts

ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026

ARDX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ardelyx between January 13, 2025 and August 6, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 20, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

ARDX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Tuesday, November 3, 2026, at 4:30 p.m.

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. So what: If you purchased Ardelyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

New York, New York--(Newsfile Corp. - October 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ardelyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc.

Ardelyx, Inc. faces allegations that it misled investors regarding the true state of its commercial performance and growth prospects of its two core drugs.

Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc.

See News Rankings

Price charts implemented using Lightweight Charts™